Jun. 12, 2013, 8:22 AMTeva's (TEVA -1.8%) and Active Biotech's (ATVBF.PK) oral laquinimod drug improved renal function in patients with active lupus nephritis in Phase IIa trials. Lupus is a chronic and often disabling autoimmune disease that can lead to kidney failure. Teva and Active Biotech believe the data provide the rationale for further studies of laquinimod. (PR) | 1 Comment
Mar. 21, 2013, 8:21 AMTeva (TEVA +0.25%) and Active Biotech (ATVBF.PK) say that early treatment of Multiple Sclerosis with their Laquinimod drug significantly cuts the risk of disability progression in patients, a Phase III trial shows. Additional data from an animal preclinical study demonstrates that laquinimod can restore myelination in the brain and spinal cord. (PR) | 3 Comments
Oct. 22, 2012, 10:14 AMLaquinimod, which is being developed by Teva (TEVA +1.2%) and Sweden's Active Biotech, performed well in a Phase IIa trial of patients with moderate to severe Crohns disease. The drug had a "robust, early and consistent effect on remission" and on response rates compared with a placebo. Laquinimod was also well-tolerated. (PR) | Comment!
Aug. 8, 2012, 9:41 AM
Dec. 9, 2010, 8:37 AM
There are no StockTalks on this stock yet.
ATVBF vs. ETF Alternatives
Other News & PR